Calzavara-Pinton Piergiacomo, Zanca Arianna, Arisi Mariachiara, Rossi Maria Teresa, Zane Cristina, Venturini Marina, Ortel Bernhard
Dermatology Department, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Dermatology Department, ASST Spedali Civili di Brescia, University of Brescia, Brescia,
Dermatology. 2018;234(5-6):166-172. doi: 10.1159/000491782. Epub 2018 Sep 11.
The prevalence of narrow-band ultraviolet B (NB-UVB) use in Europe for moderate and severe psoriasis is unknown, because national registries for psoriasis do not monitor this treatment.
To quantify the use of phototherapy, biologics or conventional treatments in psoriasis, in a setting where European Medicines Agency (EMA) eligibility criteria for biologics were strictly applied, and phototherapy was included among first-line treatments.
We followed a cohort of 1,090 patients who were referred to the only centre entitled to prescribe biologics and phototherapy during a 5-year period.
The cumulative number of treatment cycles was: 1,047 with NB-UVB phototherapy, 650 with systemic treatments and 239 with biologics; 754 patients received at least 1 course of NB-UVB phototherapy, 422 at least 1 course with a systemic treatment and 137 with a biologic; 595 patients were treated only with phototherapy.
Regular use of NB-UVB as first-line treatment for moderate and severe psoriasis and adherence to the EMA eligibility criteria for biologics led to a relatively restricted use of biologics.
在欧洲，窄谱中波紫外线（NB-UVB）用于治疗中度和重度银屑病的普及率尚不清楚，因为银屑病的国家登记处并未监测这种治疗方法。
在严格应用欧洲药品管理局（EMA）生物制剂资格标准且光疗被纳入一线治疗方法的背景下，对银屑病患者使用光疗、生物制剂或传统治疗方法的情况进行量化。
我们追踪了一组1090例患者，这些患者在5年期间被转诊至唯一有权开具生物制剂和光疗处方的中心。
治疗周期的累积数量为：NB-UVB光疗1047个，全身治疗650个，生物制剂239个；754例患者接受了至少1个疗程的NB-UVB光疗，422例至少接受了1个疗程的全身治疗，137例接受了生物制剂治疗；595例患者仅接受了光疗。
将NB-UVB作为中度和重度银屑病的一线治疗方法并严格遵循EMA生物制剂资格标准，导致生物制剂的使用相对受限。
